Cargando…
Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
Even though classical Hodgkin lymphoma is highly curable, the outcome of patients with a refractory or relapsed disease has been disappointing. Multiple lines of therapy are available for patients after their first failure, and most respond to subsequent therapies. However, there is a sizable propor...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elmer Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297052/ https://www.ncbi.nlm.nih.gov/pubmed/34349851 http://dx.doi.org/10.14740/wjon1388 |